Support for onasemnogene abeparvovec in older SMA patients

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Mar 13 / Springer Healthcare

Support for onasemnogene abeparvovec in older SMA patients

Neuroscience Spinal Muscular Atrophy MDA-2022

Description

Laurent Servais discusses real-world research suggesting that onasemnogene abeparvovec is beneficial in spinal muscular atrophy patients aged 6 months and older, supporting the results of clinical trials involving younger patients.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.